Abstract

Hyperlipidemia, a common metabolic disease, is a risk factor for cardiovascular diseases, Poria cocos (PC) and Alismatis rhizoma (AR) serve as a potential treatment. A systematic approach based on transcriptome sequencing analysis and bioinformatics methods was developed to explore the synergistic effects of PC–AR and identify major compounds and potential targets. The phenotypic characteristics results indicated that the high dose (4.54 g/kg) of PC–AR reduced total cholesterol (TC), elevated high-density lipoprotein cholesterol (HDL-C) levels, and improved hepatocyte morphology, as assessed via hematoxylin and eosin (H&E) staining. Transcriptomic profiling processing results combined with GO enrichment analysis to identify the overlapping genes were associated with inflammatory responses. The cytokine-cytokine receptor interaction pathway was found as a potential key pathway using geneset enrichment analysis. Core enrichment targets were selected according to the PC–AR's fold change versus the model. Real-time quantitative PCR analysis validated that PC–AR significantly downregulated the expression of Cxcl10, Ccl2, Ccl4, Cd40 and Il-1β mRNA (P < 0.05). Molecular docking analysis revealed the significant compounds of PC–AR and the potential binding patterns of the critical compounds and targets. This study provides further evidence that the therapeutic effects of PC–AR on hyperlipidemia in rats through the regulation of inflammation-related targets.

Details

Title
Efficacy of Poria cocos and Alismatis rhizoma against diet-induced hyperlipidemia in rats based on transcriptome sequencing analysis
Author
Zhou, Xiaowen 1   VIAFID ORCID Logo  ; Luo, Jingbiao 2   VIAFID ORCID Logo  ; Lin, Shuxian 2   VIAFID ORCID Logo  ; Wang, Yaxin 2   VIAFID ORCID Logo  ; Yan, Zhenqian 2   VIAFID ORCID Logo  ; Ren, Qi 3   VIAFID ORCID Logo  ; Liu, Xiaoqi 4   VIAFID ORCID Logo  ; Li, Xiantao 2   VIAFID ORCID Logo 

 Guangzhou University of Chinese Medicine, The Second School of Clinical Medicine, Guangzhou, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685) 
 Guangzhou University of Chinese Medicine, Laboratory of TCM Syndrome Essence and Objectification, School of Basic Medical Sciences, Guangzhou City, China (GRID:grid.411866.c) (ISNI:0000 0000 8848 7685) 
 Southwest Hospital, Army Medical University, Department of Rheumatology and Immunology, Chongqing, China (GRID:grid.416208.9) (ISNI:0000 0004 1757 2259) 
 NanoFCM Inc, Xiamen, China (GRID:grid.416208.9) 
Pages
17493
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2877232729
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.